(fifthQuint)U0289-405: An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the Acne System (Benzoyl Peroxide 2.

5%, Salicylic Acid 0.

5%) in Subjects With Acne.

 This open-label, multicenter, study is being conducted to obtain safety, efficacy, and satisfaction data on an Acne System (Benzoyl Peroxide 2.

5%, Salicylic Acid 0.

5%), which includes Foam Deep Cleanser (2.

5% Benzoyl Peroxide) and Foam Advanced Acne Treatment (2.

5% Benzoyl Peroxide) and Foam Rejuvenating Toner (0.

5% Salicylic Acid), in the treatment of moderate to severe acne.

 Approximately 120 male or female subjects ages 12-35 years, inclusive, with moderate or severe acne as assessed by Investigator's Global Assessment (ISGA) and lesion counts are expected to be enrolled.

 Subjects will be instructed to use all 3 study products as part of a complete acne treatment system; no reference therapy or control group will be included.

 Subjects will be instructed to apply Foam Deep Cleanser (2.

5% Benzoyl Peroxide) and Foam Advnced Acne Treatment (2.

5% Benzoyl Peroxide) to the face each morning and Foam Deep Cleanser (2.

5% Benzoyl Peroxide) and Foam Rejuvenating Toner (0.

5% Salicylic Acid) each evening over an application period of 12 weeks.

.

 U0289-405: An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the Acne System (Benzoyl Peroxide 2.

5%, Salicylic Acid 0.

5%) in Subjects With Acne@highlight

This study is being conducted to obtain safety, efficacy, and satisfaction data on the combination of topical Benzoyl Peroxide (BPO) 2.

5% and the topical keratolytic agent Salicylic Acid (SA) 0.

5% in the treatment of moderate to severe acne.

 Subjects with moderate or severe acne will be asked to apply the commercially available, over-the-counter products Foam Deep Cleanser (2.

5% BPO), Foam Advanced Acne Treatment (2.

5% BPO), and Foam Rejuvenating Toner (0.

5% SA) daily for 12 weeks.

 No control group or reference treatment will be included.

